Clinical Obstetrics and Gynecology 1999: Vol 42 Index

39 Pages·1999·6.8 MB·English

Cumulative
Index
Volume 42, Numbers 1—4, 1999
Abdominal delivery, elective, protective effect against Acupuncture, for pain relief, 664
childbirth-related perineal trauma, 820 Acute fatty liver of pregnancy, 551
Abdominal hysterectomy, 939 clinical presentation of, 551
and vaginal hysterectomy, comparison of, 939 comorbidity with, 551
Abdominal pregnancy, 2, 31 differential diagnosis of, 381, 532
mortality rate in, 31 epidemiology of, 551
Abdominal wall, endometriosis of, 699 laboratory findings in, 532, 551
in males, 699 outcomes with, 55]
Abortion pathophysiology of, 551
early induced thrombocytopenia with, 327
complications of, management of, 290 treatment of, 551
evaluation of patient for, 290 Acyclovir
failed, management of, 290 for herpes simplex virus, 149
frequency of, 290 for neonatal herpes, 81, 134
hemorrhage with, management of, 290 in pregnancy
incomplete, management of, 290 pharmacokinetics of, 134
medical regimens for, 290 safety of, 134
method for, selection of, 290 Acyclovir suppression
office management of, 290 animal studies on, 134
patient preparation for, 290 and asymptomatic shedding, 134
pelvic infection after, management of, 290 trials of, in pregnancy, 134
surgical methods for, 290 Addiction, 664
uterine perforation in, management of, 290 Adenocarcinoma, of endometriotic origin, 699
failed, management of, 290 Adenomyosis, versus endometriosis, 664
first-trimester surgical, 290 Adhesions
operative techniques for, 290 intrauterine, hysteroscopic treatment of, 276
pain management for, 290 and pelvic pain, 633
postoperative care for, 290 surgical management of, 633, 664
postoperative tissue examination, 290 Adnexal mass. See also Ovarian cancer; Ovarian tumor
setting for, 290 diagnosis of, color flow Doppler ultrasound in, 902
supplies for, 290 B-Adrenergic agents, tocolytic therapy using, 802
incomplete, management of, 290 in combination regimens, 802
induced B-Adrenergic receptor antagonists
frequency of, 290 for acute severe hypertension in pregnancy, 519
medical regimens for, 290 for mild gestational hypertension/preeclampsia, 455
symptoms and side effects, management of, 290 Advanced Breast Biopsy Instrumentation, 234
methotrexate-misoprostol method, 290 AFI. See Amniotic fluid index
mifepristone-misoprostol method, 290 AFS (American Fertility Society). See American Society
mifepristone-prostaglandin method, 290
for Reproductive Medicine
vacuum aspiration for, 290 Agglutination test, for toxoplasmosis diagnosis, 81, 149
spontaneous, 9. See also Termination of pregnancy
lanine aminotransferase
and cervical pregnancy, 9
in HELLP syndrome, 381, 532
Accessory spleen, 664
and hepatitis C, 121
Acebutolol, for mild gestational hypertension/pre-
Alcohol use, maternal, and pregnancy outcome, 725
eclampsia, 455
Alloimmune thrombocytopenia, 335
Acne, androgen replacement therapy and, 883
antigens causing, 33 5
Activated pr4o2te2i n C resistance, and preeclampsia risk, clinical features of, “3i
clinical history with,
complications of
fetal, 335
Page numbers indicate first page of relevant article. neonatal, 335, 368
CLINICAL OBSTETRICS AND GYNECOLOGY VOLUME 42 NUMBER 4 DECEMBER 1999
1004
Cumulative
Index
Volume 42, Numbers 1—4, 1999
Abdominal delivery, elective, protective effect against Acupuncture, for pain relief, 664
childbirth-related perineal trauma, 820 Acute fatty liver of pregnancy, 551
Abdominal hysterectomy, 939 clinical presentation of, 551
and vaginal hysterectomy, comparison of, 939 comorbidity with, 551
Abdominal pregnancy, 2, 31 differential diagnosis of, 381, 532
mortality rate in, 31 epidemiology of, 551
Abdominal wall, endometriosis of, 699 laboratory findings in, 532, 551
in males, 699 outcomes with, 55]
Abortion pathophysiology of, 551
early induced thrombocytopenia with, 327
complications of, management of, 290 treatment of, 551
evaluation of patient for, 290 Acyclovir
failed, management of, 290 for herpes simplex virus, 149
frequency of, 290 for neonatal herpes, 81, 134
hemorrhage with, management of, 290 in pregnancy
incomplete, management of, 290 pharmacokinetics of, 134
medical regimens for, 290 safety of, 134
method for, selection of, 290 Acyclovir suppression
office management of, 290 animal studies on, 134
patient preparation for, 290 and asymptomatic shedding, 134
pelvic infection after, management of, 290 trials of, in pregnancy, 134
surgical methods for, 290 Addiction, 664
uterine perforation in, management of, 290 Adenocarcinoma, of endometriotic origin, 699
failed, management of, 290 Adenomyosis, versus endometriosis, 664
first-trimester surgical, 290 Adhesions
operative techniques for, 290 intrauterine, hysteroscopic treatment of, 276
pain management for, 290 and pelvic pain, 633
postoperative care for, 290 surgical management of, 633, 664
postoperative tissue examination, 290 Adnexal mass. See also Ovarian cancer; Ovarian tumor
setting for, 290 diagnosis of, color flow Doppler ultrasound in, 902
supplies for, 290 B-Adrenergic agents, tocolytic therapy using, 802
incomplete, management of, 290 in combination regimens, 802
induced B-Adrenergic receptor antagonists
frequency of, 290 for acute severe hypertension in pregnancy, 519
medical regimens for, 290 for mild gestational hypertension/preeclampsia, 455
symptoms and side effects, management of, 290 Advanced Breast Biopsy Instrumentation, 234
methotrexate-misoprostol method, 290 AFI. See Amniotic fluid index
mifepristone-misoprostol method, 290 AFS (American Fertility Society). See American Society
mifepristone-prostaglandin method, 290
for Reproductive Medicine
vacuum aspiration for, 290 Agglutination test, for toxoplasmosis diagnosis, 81, 149
spontaneous, 9. See also Termination of pregnancy
lanine aminotransferase
and cervical pregnancy, 9
in HELLP syndrome, 381, 532
Accessory spleen, 664
and hepatitis C, 121
Acebutolol, for mild gestational hypertension/pre-
Alcohol use, maternal, and pregnancy outcome, 725
eclampsia, 455
Alloimmune thrombocytopenia, 335
Acne, androgen replacement therapy and, 883
antigens causing, 33 5
Activated pr4o2te2i n C resistance, and preeclampsia risk, clinical features of, “3i
clinical history with,
complications of
fetal, 335
Page numbers indicate first page of relevant article. neonatal, 335, 368
CLINICAL OBSTETRICS AND GYNECOLOGY VOLUME 42 NUMBER 4 DECEMBER 1999
1004
Index 1005
cordocentesis in deficiency, postmenopausal, 883
determination of need for, 335 and lipoprotein metabolism, 883
indications for, 335 Androgen replacement therapy
diagnosis of, 335 administration of, 883
in female relatives of patient, 33:5 adverse effects and side effects of, 883
fetal and bone density, in postmenopausal women, 883
natural history and estrogen replacement, combined, postmenopausal
treatment of. benefits of, 883
genetics of, 335 and libido, 883
laboratory features of, and mood, 883
neonatal, 335 psychological benefits of, 883
incidence of, 368 and vasomotor symptom relief, 883
IVIG for, 368 Androstenedione, circulating leveis of, postmenopausal
pathophysiology of, 327 changes in, 883
treatment of, 368 Anemia, with parvovirus infection, 107
pathophysiology of, 335 aplastic crisis in, 107
screening for, 335 in immunocompromised patients, 107
subsequent pregnancy after, 335 Anesthesia
diagnostic testing in, 335 in Bernard-Soulier syndrome, 390
treatment of, 335 in congenital platelet dysfunction disorders, 390
Alpha-fetoprotein postoperative, management of, 664
elevation of, antepartum surveillance for, 766 Angiogenesis, in ovarian cancer, 902
maternal serum, for parvovirus diagnosis, 107 Angiogenic growth factors, in endometriotic lesions,
Alternative medicine, 306 566
for endometriosis-related pain, 664 Anovulation, with endometriosis, 586
Ambulatory gynecology, 183 Antibiotics, lupus induced by, 381
American Academy of Family Physicians, on neonatal Anticardiolipin antibodies
circumcision, 849 in antiphospholipid syndrome, 368
American Academy of Pediatrics, on neonatal circum- and endometriosis, 979
cision, 849 laboratory detection of, 979
American College of Obstetricians and Gynecologists and preeclampsia risk, 422
guidelines for vaginal birth after cesarean section, 836 Anticholinergic therapy
recommendations, for prenatal care, 725 adverse effects and side effects of, 249
recommendations for antepartum surveillance in post- for urinary incontinence, 249
term pregnancy, 766 Antiepileptic agents, lupus induced by, 381
American College of Radiology, classification of mam- Antifungal therapy
mography results, 234 for vulvar vestibulitis, 945
American Fertility Society. See American Society for for vulvovaginal candidiasis, 184
Reproductive Medicine Antigen capture assay, in phase III antiplatelet antioody
American Society for Reproductive Medicine, classifi- assay, 317
cation (staging) of endometriosis, 611, 645, Antigenemia tests, in perinatal infections, 59
664, 699 Antthypertensives
Revised (R-AFS), 611 for acute severe hypertension in pregnancy, 519
Amniocentesis oral administration of, 519
in HELLP syndrome, 381 parenteral administration of, 519
for parvovirus diagnosis, 107 in HELLP syndrome, 532
Amnioinfusion, in vaginal birth after cesarean section, lupus induced by, 381
836 for mild gestational hypertension, 455
Amniotic fluid for preeclampsia, 455, 519
abnormalities of, sonographic findings, 71 in expectant management, 470
meconium-stained, risks associated with, 766 intrapartum, 455
Amniotic fluid index, 71 and preeclampsia prevention, 436
Amniotomy, for induction of labor, 757 and seizure prophylaxis, in preeclampsia/eclampsia,
Ampullary pregnancy, 9 507
Anal canal, endometriosis in, 699 Antinuclear antibodies, and endometriosis, 979
Analgesia Antiphospholipid antibody syndrome
for endometriosis-related pain, 620 clinical features of, 368, 979
epidural. See Epidural analgesia diagnosis of, 979
for pelvic pain, 620, 664 and HELLP syndrome,
postoperative, management of, 664 heparin and low-dose aspirin therapy in, 436, 979
for trial of labor after cesarean delivery, 836 [VIG for, 368, 979
Anal sphincter, childbirth-related damage to, 820 laboratory features of, 368, 979
Anatomic abnormalities, with endometriosis, 586 and preeclampsia risk, 422
Androgen(s) and pregnancy, 551
circulating levels of, postmenopausal changes in, 883 pregnancy-associated
1006 INDEX
complications of, 368 Autoimmune disease
outcomes with, 368 platelet dysfunction in, 349, 360
treatment of, 368 and thrombotic thrombocytopenic purpura, associa-
recurrent pregnancy loss with, 368, 979 tion of, 360
aspirin, heparin, and prednisone therapy for, 979 Autoimmune thrombocytopenic purpura
therapy for, 979 in children and adolescents, 317
thrombocytopenia with, 327 clinical presentation of, 317
Antiplatelet agents, in prevention of preeclampsia, 436 course of, 317
Antiplatelet antibodies diagnosis of, 31
in alloimmune thrombocytopenia, 335, 368 differential diagnosis of, 317
testing for, 335 epidemiology of, 317
assays for, 317 laboratory findings in, 317
phase I, 317 management of, 317
phase II, 317 obstetric considerations in, 317
phase III, 317 pathophysiology of, 317
in autoimmune thrombocytopenia, 317 in pregnancy
in idiopathic thrombocytopenic purpura, in pre i fetal complications of, 317
a9
nancy, 327 management of, 317
in thrombocytopenia, testing for, 349 neonatal complications of, 317
Antiprogestins, for endometriosis, 620 pregnancy-associated, 368
Antisperm antibodies. See Sperm antibodies [VIG therapy for, 368
Antiviral therapy, for herpes, 134 Autoimmunity, with endometriosis, 586
Aplastic crisis AutoPap, 206
causes of, 107 in cervical cancer screening, evaluation of, 922
diseases associated with, 107 Autoregulation, cerebral, loss of, and hypertensive en-
with parvovirus infection, 107 cephalopathy, 519
Aromatase production, in endometriotic lesions, 566 Ayre spatula, in cervical cancer screening, evaluation of,
ART. See Assisted reproductive technologies 9272
Arthralgias, and parvovirus infection, 107 Azathioprine, for autoimmune thrombocytopenic pur-
Arthritis, and parvovirus infection, 107 pura, 317
Ascites, in preeclampsia, 455 Azithromycin, for syphilis, 97
Ascorbic acid, serum, in preeclampsia, 436
Aspartate aminotransferase Bacterial infection, and vulvar vestibulitis, 945
in HELLP syndrome, 381, 53 yy Bacterial vaginosis, 184
testing for, specificity and sensitivity of, 163 clinical associations with, 184
Aspirin diagnosis of, 184
for antiphospholipid syndrome, 368 microbiology of, 184
antiplatelet effects, 349, 390 pathogenesis of, 184
for immune-associated pregnancy failure, 979 and preterm birth, 184
low-dose recurrence of, 184
in antiphospholipid syndrome, 4 36 treatment of, 184
in prevention of preeclampsia, 4 3n€d nonresponders, management of, 184
Assisted reproductive technologies, 2 See also Infertil- in pregnancy, 184
ity Bagel sign, of ectopic pregnancy, 39
diagnosis of ectopic pregnancy and, 9 Balanoposthitis, 849
for endometriosis-associated infertility, 68 Battey’s operation, 939
cost analysis for, 687 Bayes’ Theorem, 163
indications for, 687 B-cells
outcomes, in research, 687 fetal, 59
pregnancy rates with, 687 nonspecific polyclonal, activation, with endometrio-
research, outcomes in, 687 sis, 586
severity of disease and, 687 Beckwith-Wiedemann syndrome
types of, 687 antepartum surveillance for, 766
AST. See Aspartate aminotransferase follow-up with, 766
Asymptomatic shedding, of herpes, 134, 149 pathophysiology of, 766
acyclovir suppression and, 134 Bed rest, in prevention of preeclampsia, 436
Atenolol, for mild gestational hypertension/preeclamp- Behavioral therapy, for vulvar vestibulitis, 945
sia, 455 Benzathine penicillin G
Atosiban, tocolytic therapy using, 802 allergy to, 97
Autoantibodies for syphilis, 97, 149
and endometriosis, 979 Bernard-Soulier syndrome, 349
and infertility, 979 anesthesia considerations with, 390
prevalence of, in in vitro fertilization patients, 979 family/personal history in, 390
and recurrent pregnancy loss, 979 hemorrhagic complications of, 390
and in vitro fertilization failure, 979 laboratory diagnosis of, 390
Index 1007
pathophysiology of, 390 laboratory evaluation of, 349
platelet aggregation patterns in, 349 Blood, peripheral, cytokines in, and endometriosis, 566
pregnancy management in, 390 Blood pressure. See also Hypertension
antepartum measures for, 390 control, in HELLP syndrome, 532
intrapartum measures for, 390 in HELLP syndrome, 381
postpartum measures for, 390 in hemolytic-uremic syndrome, 360
prenatal diagnosis of, 390 measurement of, 455
Beta-mimetics in pregnancy, 455
cardiovascular effects of, 802 in thrombotic thrombocytopenic purpura, 360
metabolic effects of, 802 Bone densitometry, 876
respiratory effects of, 802 in estrogen-deficient women, 876
tocolytic therapy using, 802 for evaluation of bone mass changes in response to
administration of, 802 therapy, 876
adverse effects and side effects of, 802 in heparin-induced osteoporosis, 876
agents for, 802 indications for, 876
in combination regimens, 802 in osteopenia, 876
fetal effects of, 802 in primary hyperparathyroidism, 876
maternal effects of, 802 radiographic, 876
Bethesda System, 206 with spinal roentgenographic abnormalities, 876
Biofeedback, for bladder control in incontinence, 249 in steroid therapy, 876
Biopsy techniques for, 876
bone marrow, in autoimmune thrombocytopenia, 317 Bone loss
of breast mass, 234 postmenopausal, prevention of, 863, 876
endometrial, and endometrial cancer screening, 267 with steroid therapy, 876
liver, for hepatitisC diagnosis, 121 treatment of, efficacy of, evaluation using bone den-
uterine, dilation and curettage for, 276 sitometry, 876
Birth asphyxia, in macrosomic infants, 766 Bone marrow
Birth weight biopsy, in autoimmune thrombocytopenia, 317
factors affecting evaluation, in thrombocytopenia, 349
constitutional, 766 suppression, with parvovirus infection, 107
environmental, 766 Bone mass
genetic, 766 age and, 876
hormonal, 766 measurement of, 876
metabolic, 766 postmenopausal, androgen replacement and, 883
predictors of, 725 response to therapy, evaluation using bone densitom-
prenatal care and, 725 etry, 876
prenatal estimation of, 766 Bone mineral density
Bishop, Edward H., observations and suggestions on and bone strength, 876
induction of labor, 757 and fracture risk, 876
Bishop score, 757 postmenopausal hormone replacement and, 883
Bladder Bowel, hyperechoic, sonographic findings, 71
dysfunction. See Urinary incontinence Brachial plexus injury
endometriosis in, 699 with macrosomia and shoulder dystocia, 766
ir: males, 699 in macrosomic infant, 766
leak point pressure, 249 BRCAI and BRCA2 gene mutations, and breast/ovarian
Bladder neck suspension, percutaneous, safety and effi- cancer syndrome, 267
cacy of, 939 Breast(s)
Bleeding. See also Hemorrhage abscesses in, 234
abnormal adenosis in, 234
with endometrial cancer, 267 apocrine metaplasia of, 234
endometriosis-related, 620 atypical ductal hyperplasia in
with leiomyomata, 196 cancer risk with, 234
in autoimmune thrombocytopenic purpura, 317 ductal involvement by cells of, cancer risk with,
with early induced abortion, management of, 290 23
with heparin thromboprophylaxis, 895 benign disease of. See also Fibrocystic change; Fibro-
intracranial, in autoimmune thrombocytopenic pur- cystic disease
pura, 317 classification of, 234
mucocutaneous, in platelet dysfunction, 390 clinical features of, 234
in thrombocytopenia, 327 diagnostic workup of, 234
uterine evaluation of, 234
abnormal, hysteroscopy for, 276 history-taking in, 234
profuse, as contraindication to hysteroscopy, 276 nonproliferative, pathology of, 234
vaginal, tocolytic therapy and, 802 office management of, 234
Bleeding disorders, platelet-type, evaluation for, 349 pathology of, 234
Bleeding time, 390 prevalence of, 234
1008 INDEX
proliferative, pathology of, physical examination of, 234
symptom assessment in, 23 physiologic cyclic swelling and tenderness of, 234
terminology for, 234 proliferative benign disease of, 234
calcifications in, 234 atypical, 234
complex sclerosing lesions of, 234 without atypia, 234
cystic change in, 23 radial scars in, 234
cysts in, gross, 234 sclerosing adenosis in, 2
ductal carcinoma in situ cancer risk with, 234
cancer risk with, 234 self-examination of, 234
differential diagnosis of, 234 skin changes, evaluation and management of, 234
ductal hyperplasia in, 234 subareolar abscess in, 234
atypical, 234 symptom assessment, 234
cancer risk with, 234 Breast cancer
mild, 234 in breast/ovarian cancer syndrome, 267
moderate and florid, 234 diagnosis of, 234
examination of, 234 epidemiology of, 863
patient education about, 234 estrogen receptors in, 863
fibroadenoma in, 234 incidence of, 234
fibrocystic change in, misdiagnosis of, 234
fibrocy; stic dais ease of, mortality from, 234
fibrosis in nipple discharge with, 234
fibrotic change in, 5 progesterone receptors 1n, 863
fibrous disease of, nm prognosis for
galactocele in, 234 factors affecting, 863
infections of, 234 hormone receptor status and, 863
inflammation of, 234 risk assessment, 234
intraductal papillomas in, 234 risk factors for, 234
cancer risk with, 234 risk of, pathology of biopsied lesion and, 234
lobular carcinoma in situ screening for, 234
cancer risk with, 234 survivors, estrogen replacement therapy for, 863
differential diagnosis of, 234 Breastfeeding
lobular hyperplasia in in autoimmune thrombocytopenic purpura, 317
atypical, 234 and hepatitis C transmission, 121
cancer risk with, 234 Breast Imaging Reporting and Data System, 234
lumps in Breech presentation, vaginal birth after cesarean section
cyclic and noncyclic, 23 with, 836
dominant, 234 Bruising, in thrombocytopenia, - 327
macrocysts in, 234 Brush
mammary duct ectasia in, 23 ectocervical, in cervical cancer screening, evaluation
masses in of, 922
diagnosis of, 234 endocervical, in cervical cancer screening, evaluation
of, 922 :
fine-needle aspiration of,
lumpectomy for, 234 Burch colposuspension,
magnetic resonance for genuine stress incontinence, 249, 939
mammography for, laparoscopic, validity of, 939
nuclear scan of, 234 Buserelin acetate, for endometriosis, 620, 645
open surgical biopsy of, Butoconazole
physical examination of, vaginal cream, as vulvar irritant, 221
stereotactic needle biopsy of, for vulvovaginal candidiasis, 184
ultrasound of, 234
mastitis in 4 125, serum levels, and ovarian cancer screening, 267
acute, in cystic disease, 234 Calcitonin, for osteoporosis, 876
intrinsic, 234 ‘alcium, dietary supplementation with, in prevention of
lactational, 2: preeclampsia, 436
periductal, 234 Calcium channel blockers. See also Nicardipine; Nifed-
in Mondor disease, 234 ipine
nipple changes, evaluation and management of, tocolytic therapy using, 802
nipple discharge from, 234 Calcium oxalate crystals, and vulvar vestibulitis, 54
in benign disease, 234 Cancer
with cancer, 234 angiogenesis in, 902
surgically significant, 234 breast. See Breast cancer
types of, 234 endometrial. See Endometrial cancer
nodularity of, 234 gynecologic. See Gynecologic cancer
nonproliferative benign disease of, 234 ovarian. See Ovarian cancer
pain in, cyclic and noncyclic, 234 penile, prevention of, circumcision and, 849
Index 1009
vulvar. See Vulva, cancer of Cerebral vasculature, Doppler ultrasound studies of, in-
Candidiasis dices for, 479
and cyclic vulvovaginitis, 221 Cerebral ventriculomegaly, sonographic findings, 71
and vulvar vestibulitis, 221, 945 Cervex brush, in cervical cancer screening, evaluation
vulvovaginal, 184 of, 922 :
chronic, management of, 184 Cervical cancer
complicated, management of, 184 adenocarcinoma in situ, management of, 916
diagnosis of, 184 as contraindication to hysteroscopy, 276
incidence and prevalence of, 184 HPV infection and, 206, 267, 849
oral therapy for, 184 microinvasive squamous, management of, 916
pathophysiology of, 184 prevention, male circumcision and, 849
predisposing factors, 184 risk factors for, 267
in pregnancy, 184 screening for. See Cervical cancer screening
recurrent, management of, 184 Cervical cancer screening, 267
signs and symptoms of, 184 conventional smears for
topical therapy for, 184 with adjunctive reinterpretation of negative smears,
reatment of, 184 evaluation of, 922
vulvar care measures for, 184 with computerized interpretation
Capsaicin, topical, for vulvar vestibulitis, 945 & f|¢ f ectiveness of, studies of, 922
Carbamazepine, lupus induced by, 381 e i ficacy of, studies of, 922
Carbon dioxide, insufflation, for uterine distention, 176 sensitivity of, studies of, 922
C"aI rbon dioxide l] aser treatment, f‘ or genital warts, 206 spseeccitiffiicciittsy of, . studies> of,> g9o2od2
efficacy and effectiveness of, evaluation of, 922
Carcinoma, of endometriotic origin, 699
sensitivity and specificity of, evaluation of, 922
Cardiac abnormalities, sonographic findings, 7
effects on woman’s quality of life, 922
Cardiac failure
in HIV-infected (AIDS) patients, 267
beta-mimetic-induced, 802
liquid-based smears for
in macrosomic infants, 766
and conventional smears, comparison of sensitivity
Cardiac output, in hypertension, 519
and specificity of, 922
Cardiomegaly, sonographic findings, 71
sensitivity and specificity of, evaluation of, 922
Cardiovascular disease, postmenopausal
modalities for, 267
androgen replacement therapy and, 883
in older women, 267
estrogen replacement therapy and, 863, 883
Pap smear for, 267
prevention of, 863, 883
population-based
B-Carotene, serum, in preeclampsia, 436
Cats, and toxoplasmosis, 81, 149 cost-effectiveness analysis of, 922
economics of, 922
Ceftriaxone, for syphilis, 97
important considerations for, 922
Cell-mediated immunity, abnormalities, with endometri-
recommendations for, 267
osis, 586
sampling errors in, 922
Central nervous system smear interpretation in, errors in, 922
endometriosis of, 699 techniques, 922
malformations, with parvovirus infection, techniques for, recommendations for, 0099 22
Cerebral blood flow
tests [or
in hypertensive encephalopathy, 519 effectiveness of, 922
in preeclampsia, 479
efficacy of, 922
in pregnancy, 479 evaluation of,
Cerebral blood velocity sensitivity and specificity of, determination of rel-
in normal pregnancy ative changes in, 922
central hemodynamic indices and, 479 sensitivitiyty Of,£ QD?
mean arterial pressure and, 479 specific“iPte y off , 92O297
in preeclampsia, 479 true sensitivity and specificity of, determination of,
Cerebral edema, in macrosomic infants, 766 079
Cerebral hemodynamics two or more, comparing sensitivities and specific-
in normal pregnancy, 479 ities of, 922
in preeclampsia, 479 Cervical intraepithelial neoplasia
Cerebral perfusion pressure HPV types associated with, 206
estimation of, 479 treatment of, 206
in normal pregnancy, 479 Cervical pregnancy, 2, 9, 31
in preeclampsia, 479 sonography in, 9
high, management protocol for, 479 Cervical ripening, prostaglandins for, 749
low, management protocol for, 479 with vaginal birth after cesarean section, 836
magnesium sulfate therapy and, 479 Cervicography, in HPV infection, 206
management protocol for, 479 Cervix, uterine
nimodipine therapy and, 479 cancer of. See Cervical cancer
normal, management protocol for, 479 condition of
1010 INDEX
Bishop score for, 757 risks of, critical anaiysis of, 849
and elective induction of labor, 757 and sexually transmitted disease prevention, 849
cytology and sexual sensation and satisfaction, 849
and endometrial cancer screening, 267 surgical complications of, 849
specimen collection and processing for, 922 surgical techniques for, 849
specimen interpretation for, 922 and urinary tract infection prevention, 849
endometriosis of, 699 ‘irrhosis, and hepatitis C, 121
infection, as contraindication to hysteroscopy, 276 lear-cell carcinoma, of endometriotic origin, 699
in sexual response, 972 Clindamycin, for bacterial vaginosis, 184
Cesarean delivery. See also Vaginal birth after cesarean adverse effects and side effects of, 184
section linical recommendations, strength of, rating system
elective, with macrosomia, candidates for, 766 for, 849, 972
in HELLP syndrome, 381 ‘lonidine
for infants of diabetic mothers, 766 for acute severe hypertension in pregnancy, 519
and neonatal herpes prevention, 134 for menopausal vasomotor symptoms, 863
cost-benefit analysis on, 134 for mild gestational hypertension/preeclampsia, <
rates of, 836 lotrimazole
repeat, rates of, 836 vaginal cream, as vulvar irritant, 221
risk of for vulvovaginal candidiasis, 184
with premature rupture of membranes, 749 MV. See Cytomegalovirus
timing of epidural placement and, 785 oagulopathy
trial of labor after in HELLP syndrome, 532
amnioinfusion in, 836 and preeclampsia risk, 422
anesthesia for, 836 ‘oitus, endometriosis-related pain and, 664
candidates for, 836 Cold knife conization, and loop electrosurgical excision
clinical considerations for, 836 procedure, comparison of, 916
complications of, 836 ‘ollagen
and delivery, 836 changes in, in injury and wound healing, 820
failure of, 836 in connective tissue, 820
management of, 836 periurethral injections, for incontinence, 249
monitoring during, 836 type I, 820
success rates for, 836 type HI, 820
uterine dehiscence after, 836 ‘ollagen receptor defects
uterine rupture after, 836 diagnosis of, 390
Chancre, in primary syphilis, 97 pathophysiology of, 390
hediak-Higashi syndrome, 390 treatment of, 390
‘hildbirth. See also Vaginal birth after cesarean section ollagen vascular disease
pelvic floor damage in, 820. See a/so Perineal trauma, differential diagnosis of, 381
childbirth-related and pregnancy, 551
perineal trauma in, 820. See also Perineal trauma, Color flow Doppler ultrasound
childbirth-related aliasing in, 902
‘hlamydia infection artifacts in, 902
and endometriosis, differentiation of, 664 color gain for, 902
and vulvar vestibulitis, 945 color priority for, 902
‘hlorpromazine, hepatotoxicity of, 381 for ectopic pregnancy diagnosis, 39
holestasis, drug-induced, 381 flow velocity for, 902
‘hromosomal abnormalities, and preeclampsia risk, 422 imaging parameters for, 902
Cigarette smoking, 24 normal ovarian blood flow on, 902
Circumcision, neonatal in ovarian cancer diagnosis, 902
anesthetic techniques for, 849 accuracy of, 902
benefits of, critical analysis of, 849 in cluster or sequence of diagnostic tests, 902
and cervical cancer prevention, 849 receiver operator characteristic curves for, 902
cost-effectiveness of, 849 resistive index for, 902
and foreskin retraction difficulties, 849 studies of
and HIV infection prevention, 849 and comparison with gold standard of diagnosis,
and inflammatory penile disorders, 849 902
pain and distress inflicted by, 849 evaluation of, 902
parental preferences regarding, factors affecting, 849 exclusion criteria for, 902
and penile cancer prevention, 849 inclusion criteria for, 902
and penile problems, 849 observer variation in, 902
professional organizations’ positions on, 849 patient sample for, 902
rates of, 849 percent premenopausal patients in, 902
recommendation of practice setting and, 902
clinical experience and, 849 reproducibility of results in, 902
scientific evidence and, 849 sample size in, 902
Index 1011
technology description in, 902 Cytokine production, and endometriosis, 566
test characteristics in, 902 Cytolysis of vaginal epithelium, 221
and treatment planning, 902 ytomegalovirus
usefulness of, studies of, 902 antibodies to, 81, 149
range ambiguity in, 902 congenital. See also TORCH infections
sample volume for, 902 adverse outcomes with, 59, 81
technology of, 902 asymptomatic, 81
wall filters for, 902 chemoprophylaxis for, 81
Colpocentesis, 9 clinical findings, 81
Colporrhaphy, anterior, for genuine stress incontinence, developmental delay with, 81
249 hearing loss with, 59, 81
Colposcopy laboratory findings, 81
indications for, 206 long-term sequelae, 59, 81
with vulvar vestibulitis, 221 prevention of, 81
Complementary medicine, 306 radiologic findings, 81
Complement fixation test, for toxoplasmosis diagnosis, sequelae of, 59, 81
81 treatment for, 81
Compression devices, for thromboprophylaxis, 895 course of, 149
Compression stockings, for thromboprophylaxis, 895 culture of, 59, 149
Computed tomographic scan, 9 diagnosis of, 59, 149
Condyloma disease and infection, difference between, 149
definition of, 206 epidemiology of, 81, 149
HPV types associated with, 206 and human immunodeficiency virus, 149
Condyloma lata, 206 maternal infection
Congenital anomalies, structural, and preeclampsia risk, primary, 81
422 recurrent, 81
Connective tissue overview of, 81
childbirth-related damage to, 820 prevention of, 149
composition of, 820 retinitis caused by, 149
disorders, and genital prolapse, 820 screening for, 149
Cordocentesis sonographic evaluation of, 71
risks with, 59 validity of, 71
for toxoplasmosis diagnosis, 81 transmission of, 81
Cornual pregnancy, 2, 9 treatment for, 81
sonography in, 9 vaccine for, 81
Corpus luteum cyst, hemorrhagic, 9 Cytotoxic agents, direct injection of, 23
Corpus luteum insufficiency, with endometriosis,
Corticosteroids Danazol
for HELLP syndrome, 532 anabolic side effects of, 620
for immune-associated pregnancy failure, 979 androgenic side effects of, 620, 645
for thrombotic thrombocytopenic purpura, 551 for autoimmune thrombocytopenic purpura, 317
for vulvar vestibulitis for endometriosis, 620
oral administration of, 945 adverse effects and side effects of, 620
topical administration of, 945 dosage and administration of, 620
Counseling, with ultrasound screening in pregnancy, and gastrointestinal involvement, 699
tan and related pain, 645, 664
Creatine kinase, in diagnosis of ectopic pregnancy, 9 results with, 620
Creatinine, serum, in preeclampsia, 455 and urinary tract involvement, 699
Cryotherapy Dapsone
indications for, 916 for autoimmune thrombocytopenic purpura, 317
and loop electrosurgical excision procedure, compar- for toxoplasmosis, 149
ison of, 916 Darkfield microscope, for syphilis diagnosis, 97
Culdocentesis, 9 Deafness, with congenital cytomegalovirus, 81
Curettage Death, leading causes of, in women, 306
cervical, in cervical pregnancy, 2, 31 Deep venous thrombosis, in gynecologic surgical pa-
in diagnosis of ectopic pregnancy, 9 tients
Cyclic vulvovaginitis, 221 heparin therapy for, 895
diagnosis of, 221 mechanical thromboprophylaxis for, 895
treatment of, 221 prevention of, 895
Cyclophosphamide, for autoimmune thrombocytopenic rates of, 895
purpura, 317 risk factors for, 895
Cyproterone acetate, for endometriosis, 620 Dehydroepiandrosterone
Cystocele, 249 adverse effects and side effects of, 883
Cystourethropexy, safety and efficacy of, 939 and bone density, 883
Cystourethroscopy, dynamic water, 249 circulating levels of, postmenopausal changes in, 883
1012 INDEX
Dehydroepiandrosterone sulfate, circulating levels of, in Ovarian cancer diagnosis, 902
postmenopausal changes in, 883 transcranial
Delivery. See also Cesarean delivery; Preterm delivery compression testing technique, 479
in autoimmune thrombocytopenic purpura, 317 confounding influences on, 479
in HELLP syndrome, 381 estimation of arterial and arteriolar constriction
anesthesia for, 381 from, 479
timing of, 381 intraobserver variation in, 479
with idiopathic thrombocytopenic purpura of preg- limitations of, 479
nancy, 327 in normal pregnancy and preeclampsia, 479
management of pulse pressure area index, 479
in Bernard-Soulier syndrome, : pulse velocity area index, 479
in gestational diabetes, 766 techniques, 479
with macrosomia, 766 transtemporal approach for, 479
in von Willebrand disease, 390 Douching, vaginal, 24
in vaginal birth after cesarean section, 836 Doxycycline, for syphilis, 97
Dermatitis, vulvar, 221 Drug(s). See also spec iflc drug
Dermatoses, vulvar, 221 hepatotoxicity of, 381
Desmopressin (DDAVP), for von Willebrand disease, Dual-energy x-ray absorptiometry, for bone mass mea-
390 surements, 876
Detrol Dual-photon absorptiometry, for bone mass measure-
adverse effects and side effects of, 24‘ ments, 876
for urinary incontinence, 249 Ductus arteriosus, indomethacin and, 802
Detrusor function, physiology of, 249 Duphaston. See Dydrogesterone
Detrusor hyperreflexia, urinary incontinence with, 249 Dydrogesterone, for endometriosis, 620
Detrusor instability Dyes, as vulvar irritants, 22]
evaluation of patient for, 249 Dysesthetic vulvodynia. See Vulvodynia, dysesthetic
pathophysiology of, 249 Dysmenorrhea, endometriosis-related, 611, 620, 664
Developmental delay, with congenital cytomegalovirus, Dyspareunia
81 endometriosis-related, 611, 620, 664
Dexamethasone, for HELLP syndrome, 532 introital, 221
Dextran in dextrose, for uterine distention, 276 with vulvar vestibulitis, 945
DFA-Tp. See Direct fluorescent antibody stains Dystocia
DHEA. See Dehydroepiandrosterone and brachial plexus injury, 766
DHEAS. See Dehydroepiandrosterone sulfate diagnosis of, in trial of labor after cesarean delivery,
Diabetes insipidus, in HELLP syndrome, 381 836
Diabetes mellitus. See a/so Gestational diabetes; Infants infants of diabetic mothers and, 766
of diabetic mothers macrosomia and, 766
and preeclampsia risk, 422
Diagnostic algorithms, 9 EBV (Epstein-Barr virus) infection, perinatal. See
Diagnostic tests, criteria for, 957 TORCH infections
Diethylstilbestrol, 23 Echinocytes, in HELLP syndrome, 381
Dihydralazine, and seizure prophylaxis, in preeclamp- Eclampsia. See also HELLP syndrome; Preeclampsia
sia/eclampsia, 507 brain-capillary leak in, 519
Dilation and curettage, advantages and disadvantages of, clinical presentation of, 519
276 diagnosis of, 507
Direct fluorescent antibody stains (DFA-Tp), for syphi- differential diagnosis of, 551
lis diagnosis, 97 frequency of, in women not receiving seizure prophy-
Disseminated intravascular coagulation, : a32 laxis, 507
and HELLP syndrome, 381 and hypertensive encephalopathy, differentiation of,
in hemolytic-uremic syndrome, 360 519
in thrombotic thrombocytopenic purpura, 360 management of, 470, 507
Ditropan, for urinary incontinence, 249 pathophysiology of, 507
Diuretics prediction of, 507
for preeclampsia, 455 risk of, in HELLP syndrome, 381
in prevention of preeclampsia, 436 thrombocytopenia with, 327
Donor insemination Eclamptic convulsions
fecundity rates, in endometriosis patients, prevention of, 507. See also Seizure prophylaxis
and preeclampsia, 422 treatment of, 507
Doppler effect, 902 Econazole nitrate, for vulvovaginal candidiasis, 184
Doppler ultrasound Ectopic pregnancy
for ectopic pregnancy diagnosis, 39 bagel sign with, 39
orbital chronic, 48
intraobserver variation in, 479 classification of, 9
in normal pregnancy and preeclampsia, color flow Doppler techniques for, 39
techniques, 479 diagnosis of, 9, 39